<DOC>
	<DOCNO>NCT00980876</DOCNO>
	<brief_summary>The objective study compare efficacy safety profile test product contain 2 mg/mL ciprofloxacin hydrochloride associate 10 mg/mL hydrocortisone reference product Cipro HCÂ® , patient acute otitis externa .</brief_summary>
	<brief_title>A Comparative Study Between Two Formulations Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension</brief_title>
	<detailed_description>Phase III , non inferiority , multicentric , control , single blind , parallel-group , randomize study . Population : 224 patient external otitis , men woman age 1 - 70 year . Primary endpoint : The primary endpoint study elimination pain , swell otorrhea ( cure ) . Secondary endpoint : The endpoint identification side effect medication use .</detailed_description>
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ciprofloxacin , hydrocortisone drug combination</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Informed nature study give write informed consent ; Patients acute otitis externa ; Intact tympanic membrane . Known allergy sensitivity Ciprofloxacin Hydrochloride Hydrocortisone ; Patient tympanic membrane intact ; Diabetes Bilateral Acute Otitis Externa ; Pregnant lactating patient ; Overt fungal Acute Otitis Externa ; Other disease ear Current Infection require systemic antimicrobial therapy . Current enrollment investigational drug device study participation study within 30 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>